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Background: Macular edema is a common complication of uveitis and represents a therapeutic challenge,
especially in children. Recently, intravitreal dexamethasone implants have been shown to decrease intraocular
inflammation and to control uveitic macular edema in patients with non-infectious intermediate or posterior uveitis.
Findings: An 11-year-old boy with bilateral granulomatous idiopathic panuveitis and orbital inflammation
experienced macular edema refractory to topical steroids and subcutaneous methotrexate. He was treated with off-
label bilateral injections of dexamethasone intravitreal implant. Three months later, his vision had improved from
20/200 in both eyes to 20/30 in the right eye and 20/40 in the left eye. Optical coherence tomography showed
complete resolution of the cystoid macular edema and subretinal fluid in both eyes.
Conclusions: This is a rare report of the use of bilateral dexamethasone intravitreal implant in a pediatric patient.
The implants achieved complete resolution of the uveitic macular edema with no adverse events 3 months post-
implantation.
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Introduction
The prevalence of pediatric cases within the general
uveitis population is estimated to range from 5% to
13.8% [1-3]. The treatment of uveitis in children is chal-
lenging due to the lack of verbalization of symptoms,
difficult examination, and suboptimal compliance to the
recommended treatment [4]. Corticosteroids remain the
mainstay of treatment but are associated with unique
complications in children especially when used systemic-
ally, such as growth retardation [5-7]. Intravitreal triam-
cinolone has been used to treat uveitic macular edema
but is associated with a significant risk of increased* Correspondence: serge.bourgault.1@ulaval.ca
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methasone intravitreal implant (Ozurdex®, Allergan Inc.,
Irvine, CA, USA) has been shown to significantly im-
prove intraocular inflammation, visual acuity, and cen-
tral macular thickness in adults with non-infectious
intermediate or posterior uveitis [10]. Recently, control
of inflammation and resolution of cystoid macular
edema (CME) was achieved with dexamethasone im-
plant in 13 out of 14 eyes of patients with pediatric uve-
itis [11]. We present a rare case of a child followed for
bilateral recalcitrant uveitic macular edema despite
systemic immunosuppression who responded to dexa-
methasone intravitreal implants.Case report
An 11-year-old boy of Nigerian descent was followed for
bilateral granulomatous idiopathic panuveitis and orbital
inflammation for 14 months (Figure 1). His past medicalis an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Color fundus photographs and fluorescein angiogram at presentation. (top right and top left) Both eyes showed optic nerve
edema, dilated veins, and macular edema. (bottom right and bottom left) Late-phase fluorescein angiogram showed leakage of the optic nerve
head that was more evident in the left eye, as well as patchy hyperfluorescence of the macula and petaloid leakage at the fovea in both eyes.
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G6PD deficiency. At the onset of the disease, a rheuma-
tologic workup with anti-nuclear antibody, rheumatoid
factor, anti-neutrophil cytoplasmic antibodies, and HLA-
B27 testing was negative. Serology for Lyme disease,
toxoplasmosis, toxacariasis, cat scratch disease, human
immunodeficiency virus, leptospirosis, coccidioidomyco-
sis, and histoplasmosis was negative. Syphilis was also
ruled out by a negative RPR and TP-PA. His serum cal-
cium level was slightly elevated, but the angiotensin
converting enzyme level and chest X-ray were normal. A
biopsy of an enlarged right lacrimal gland biopsy was
performed. Pathologic analysis was inconclusive and
showed a non-specific non-granulomatous lymphocytic
inflammation. A Mantoux test result showed 4 mm of
induration and was considered positive as the patient
came from an endemic area and was at that time treated
with high-dose intravenous corticosteroids for his ocular
inflammation. The patient was treated with anti-
tuberculous triple-drug therapy for 2 months and then
with rifampin for 4 months. Triple-drug therapy was
discontinued as the patient was diagnosed with latent
tuberculosis by infectious disease specialists. Indeed, he
showed a positive response to corticosteroids, and
aqueous and vitreous fluid cultures were negative for
mycobacteria.
The patient had undergone a diagnostic vitrectomy
with intravitreal injection of triamcinolone acetonide inthe left eye 3 months after presentation for worsening of
macular edema despite treatment with subcutaneous
methotrexate for 6 weeks. The vitreous biopsy yielded
negative cultures for bacteria, mycobacteria, fungus, and
parasites. The central foveal thickness dramatically de-
creased from 1,002 μm preoperatively to 238 μm with
complete resolution of the uveitic macular edema at 1
month after surgery.
Over the last 3 months, his best-corrected visual acuity
had decreased from 20/40 in the right eye (OD) and
20/30 in the left eye (OS) to 20/200 in both eyes (OU).
Slit lamp examination showed mutton-fat keratic precip-
itates, 4+ anterior chamber cells, and 3+ flare. Both eyes
showed 4+ vitreous cells. Dilated fundus examination
showed bilateral disc edema, dilated and sheathed veins,
and macular edema. Optical coherence tomography
(OCT) showed CME and subretinal fluid with a central
foveal thickness of 592 μm OD and 435 μm OS
(Figure 2). His treatment regimen included prednisolone
drops 1% every hour, dexamethasone ointment 0.1% and
homatropine drops 2% bid OU, subcutaneous metho-
trexate 20 mg weekly, and oral folic acid 2 mg daily.
Given the refractory nature of the uveitic macular
edema despite therapeutic levels of methotrexate, the
prior positive response to intravitreal steroid and the
vitrectomized status of the left eye, off-label bilateral in-
jections of dexamethasone intravitreal implant were
performed under general anesthesia. On post-operative
Figure 2 Optical coherence tomography before bilateral injections of dexamethasone intravitreal implant. Optical coherence
tomography showed marked cystoid macular edema in the right eye. (top) The left eye showed subretinal fluid and minimal cystoid macular
edema (bottom). The central retinal thickness was 592 μm in the right eye and 435 μm in the left eye.
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phenolate mofetil 500 mg daily, which was gradually in-
creased to 750 mg bid. His visual acuity improved to 20/
80 OD and 20/50 OS 3 weeks after the injections. Three
months post-operatively, his visual acuity was 20/30 OD
and 20/40 OS. He showed fine keratic precipitates, 2+
anterior chamber cells, and 1+ vitreous cells OU. The
intraocular pressures were in the normal range and the
both eyes showed posterior subcapsular cataracts. Both
optic nerves showed reduced edema. The OCT showed
absence of CME and subretinal fluid in both eyes
(Figure 3).
The patient did not experience significant uveitic macu-
lar edema recurrence requiring local treatment over the
next 2 years. Further systemic therapy with infliximab,
which was added 11 months after the Ozurdex injections,
has achieved excellent control of his uveitis.Discussion
CME is a common complication of pediatric uveitis with
a prevalence of approximately 30% at 3 years from initial
presentation [3,6]. In a large case series of 527 pediatric
uveitis patients, CME was second only to hypotony as
the uveitic complication with the most significant visual
impact [6]. Our patient demonstrated macular edema
that was refractory to topical steroids and immunosup-
pression with methotrexate but that was exquisitely re-
sponsive to vitrectomy and intravitreal triamcinolone
acetonide in one eye.
When he experienced a second flare-up of his uveitic
macular edema, the newly available Ozurdex® implant
was considered because of its duration of action and its
stability in vitrectomized eyes. The half-life of intravi-
treal triamcinolone acetonide is shorter in a vitrecto-
mized eye, its concentration decreasing 1.5 times more
Figure 3 Optical coherence tomography 3 months after bilateral injections of dexamethasone intravitreal implant. Both eyes showed
absence of cystoid macular edema and subretinal fluid (OD, top; OS, bottom). The central retinal thickness was 338 μm in the right eye and 261
μm in the left eye.
Bourgault et al. Journal of Ophthalmic Inflammation and Infection 2013, 3:61 Page 4 of 5
http://www.joii-journal.com/content/3/1/61rapidly than in a non-vitrectomized eye [12]. On the
other hand, Ozurdex® exhibits a vitreous concentration
of dexamethasone that is sustained over time to a similar
extent in vitrectomized and non-vitrectomized eyes [13].
Moreover, pharmacokinetic and pharmacodynamic data
suggest that when injected into the posterior segment,
the implant releases dexamethasone into the vitreo-
retinal tissues for up to 6 months [14]. Three months
after the injections, our patient experienced a significant
visual acuity improvement and a normalization of his
OCT in both eyes. He did not show increased intraocu-
lar pressure but posterior subcapsular cataracts started
to develop. The methotrexate treatment was replaced by
mycophenolate mofetil around the same time that the
implants were injected and it may have assisted in the
macular edema control. Mycophenolate mofetil takes
several weeks to have an effect and probably did not play
a significant role in the initial control of the macular
edema. However, it possibly helped to keep the macula
dry after the effect of the implants wore off.
This case did not only represent a therapeutic chal-
lenge, but also a diagnostic one. Tuberculosis was first
considered as the etiology of our patient’s uveitis but
that hypothesis was later abandoned. Although a strong
suspicion for sarcoid-associated uveitis and orbital dis-
ease was raised, this diagnosis could not be confirmed
despite an extensive work-up including a biopsy of an
enlarged lacrimal gland. The etiology was therefore
labeled as idiopathic.In a previous report of the use of the Ozurdex®
intravitreal implant for the treatment of uveitis in chil-
dren, 31% of treated eyes that showed an initial response
relapsed within 6 months of their injection, at a median
time of 4 months [11]. This finding stresses the import-
ance of concomitant systemic immunosuppressive ther-
apy to achieve long-term control of ocular inflammation.
Lowder et al. showed that dexamethasone intravitreal
implant was effective in controlling ocular inflammation
and had an advantageous safety profile, with less than
10% of treated eyes having an intraocular pressure of 25
mmHg or greater and no significant increased risk of
cataract [10]. Nevertheless, they did not study the safety
profile of repeated injections. We believe that Ozurdex®
has a role in the treatment of pediatric uveitis or its
complications, such as macular edema, which are not
well controlled with systemic therapy or when compli-
ance with medication may be a problem.
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